Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Prexigebersen

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bio-Path Presents Prexigebersen AML Combo Data At EHA 2024
    Bio-Path Presents Prexigebersen AML Combo Data At EHA 2024

    14 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/14/2898892/0/en/Bio-Path-Holdings-Presents-Data-from-Ongoing-Phase-2-Combination-Study-of-Prexigebersen-for-Treatment-of-Acute-Myeloid-Leukemia-at-European-Hematology-Association-Congress.html

    GLOBENEWSWIRE
    14 Jun 2024
    Share Share
    Bio-Path's Prexigebersen AML Combo Data At ASCO 2024
    Bio-Path's Prexigebersen AML Combo Data At ASCO 2024

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892094/0/en/Bio-Path-Holdings-Presents-Data-from-Ongoing-Phase-2-Combination-Study-of-Prexigebersen-for-Treatment-of-Acute-Myeloid-Leukemia-at-American-Society-of-Clinical-Oncology-ASCO-Annual.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    Bio-Path to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen
    Bio-Path to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen

    24 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/24/2765453/0/en/Bio-Path-Holdings-to-Host-Virtual-Key-Opinion-Leader-Event-to-Discuss-Prexigebersen-and-Advances-in-the-Treatment-Landscape-for-Acute-Myeloid-Leukemia.html

    GLOBENEWSWIRE
    24 Oct 2023
    Share Share
    Bio-Path Holdings Announces Results from Phase 2 of Prexigebersen
    Bio-Path Holdings Announces Results from Phase 2 of Prexigebersen

    01 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/08/01/2715632/0/en/Bio-Path-Holdings-Announces-Positive-Results-from-Interim-Analysis-of-Phase-2-Clinical-Trial-of-Prexigebersen-in-Acute-Myeloid-Leukemia.html

    GLOBENEWSWIRE
    01 Aug 2023
    Share Share
    Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen
    Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen

    22 Oct 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/10/22/2112656/0/en/Bio-Path-Receives-Notice-of-Allowance-for-Strategic-Patent-for-Prexigebersen-in-Combination-with-Front-Line-Cytidine-Analogues-or-Bcr-Abl-Tyrosine-Kinase-Inhibitors-in-a-Variety-of.html

    GLOBENEWSWIRE
    22 Oct 2020
    Share Share
    Bio-Path Holdings Announces First Patient Dosed in Amended St2 of the Ph2 Trial
    Bio-Path Holdings Announces First Patient Dosed in Amended St2 of the Ph2 Trial

    13 Aug 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/08/13/2077779/0/en/Bio-Path-Holdings-Announces-First-Patient-Dosed-in-Amended-Stage-2-of-the-Phase-2-Clinical-Trial-Evaluating-Prexigebersen-in-Acute-Myeloid-Leukemia.html

    GLOBENEWSWIRE
    13 Aug 2020
    Share Share